| 查看: 6248 | 回复: 32 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
埃索美拉唑钠 药典标准
|
|||
|
埃索美拉唑钠 有没有药典标准呀 一直没找到... 没有的话，自己生产的话这标准是参考 埃索美拉唑镁 还是 奥美拉唑钠 |
回复此楼» 本帖已获得的红花（最新10朵）
CZX99» 猜你喜欢
硅胶柱可以用纯二氯甲烷洗脱吗
已经有17人回复
-
脑梗怎么治疗
已经有3人回复
-
药理学论文润色/翻译怎么收费?
已经有81人回复
-
脑梗怎么治疗
已经有0人回复
-
生物组织中有目标分析物，专属性怎么做
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 埃索美拉唑钠原料的开发
已经有16人回复
- 埃索美拉唑钠的重结晶方法
已经有18人回复
- 求助埃索美拉唑钠的研发背景资料
已经有8人回复
- 埃索美拉唑镁肠溶微丸释放时变色
已经有13人回复
- 大家有没有做埃索美拉唑钠项目的进来交流一下！
已经有47人回复
- 【求助】高手请进 关于埃索美拉唑钠盐的紫外图谱
已经有8人回复
- 【求助】埃索美拉唑钠
已经有17人回复
» 抢金币啦！回帖就可以得到:
-
美国密歇根州立大学林学系杜海顺课题组招收全奖博士生及联合培养博士生
+1/82
-
中科院长春光机所 招收计算材料学博士/硕士研究生（含机器学习辅助材料设计方向）
+1/81
-
华中科技大学龚江研究员课题组诚招博士研究生、科研助理和博士后
+3/48
-
2026博士申请——有机化学\计算化学\药物化学方向
+1/46
-
深圳理工大学梁国进课题组招聘研究助理教授、博后多名（电化学储能方向）
+1/41
-
征女友 @长安
+1/34
-
上海大学昝鹏教授、军事医学研究院伯晓晨研究员/倪铭副研究员 课题组招聘博士生
+2/28
-
【AI、水文方向】香港科技大学（广州）研究助理招聘
+1/26
-
南科大夏海平院士-深大张平玉课题组联合招聘博士后
+1/24
-
南京工业大学招收2026年全日制学术博士（供热、供燃气通风与空调）
+1/13
-
博士/硕士招生
+1/12
-
2026年中科院化学所优青 程靓团队招收有机化学、生物化学背景的博士研究生
+1/8
-
哈尔滨工业大学招收硕士研究生（欢迎环境、市政、生物、化学、农业等专业，长期有效）
+1/7
-
天津大学化学系吴立朋课题组申请考核制博士招生/博后招聘
+1/6
-
现在，OL的editorial review多久后才分配副编辑?
+1/5
-
上海理工大学“新能源材料”专业-赵斌教授招收申请考核制博士生【能源催化方向】
+1/4
-
深容SCI智能体四大模块：Method, Introduction, Discussion, Abstract
+1/4
-
211 院校 化学工程与技术 双一流学科 学术型博士研究生 尚有名额
+1/3
-
福州大学梁宇航副教授招收2026年申核制博士研究生/硕士研究生（理论计算方向）
+1/3
-
湖南大学机械与运载工程学院赵岩副教授课题组招生2026级普通博士生1名
+1/2
26楼2012-02-17 17:25:55
2楼2011-08-30 14:35:50
★
hao8431(金币+1):谢谢参与
hao8431(金币+1):谢谢参与
|
以下是USP34版友原料药镁盐的标准 Esomeprazole Magnesium (es'' oh mep' ra zole mag nee' zee um). C34H36MgN6O6S2·3H2O Trihydrate: 767.17 C34H36MgN6O6S2 Anhydrous: 713.12 1H-Benzimidazole,5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl], magnesium salt (2:1), trihydrate; 5-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole, magnesium salt (2:1), trihydrate [217087-09-7]. DEFINITION Esomeprazole Magnesium contains NLT 98.0% and NMT 102.0% of C34H36MgN6O6S2, calculated on the anhydrous basis. IDENTIFICATION • A. INFRARED ABSORPTION 197K • B. The Sample solution, prepared and tested as directed in the test for Content of Magnesium, exhibits a significant absorption at 285.2 nm. ASSAY • PROCEDURE Solution A: Dissolve 0.725 g of monobasic sodium phosphate and 4.472 g of anhydrous dibasic sodium phosphate in 300 mL of water, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. If necessary, adjust with phosphoric acid to a pH of 7.6. Solution B: Mix 11 mL of 0.25 M tribasic sodium phosphate with 22 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 100 mL. Mobile phase: Acetonitrile and Solution A (7:13) Standard solution: Transfer 10 mg of USP Omeprazole RS to a 200-mL volumetric flask, and dissolve in about 10 mL of methanol. Add 10 mL of Solution B, and dilute with water to volume. [NOTE—This solution contains 0.05 mg/mL of omeprazole. ] Sample solution: Transfer 10 mg of Esomeprazole Magnesium to a 200-mL volumetric flask, and dissolve in about 10 mL of methanol. Add 10 mL of Solution B, and dilute with water to volume. [NOTE—This solution contains 0.05 mg/mL of esomeprazole magnesium. ] Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 280 nm Column: 4.0-mm × 12.5-cm or a 4.6-mm × 15-cm; 5-μm packing L7. [NOTE— Alternatively, a 3.9-mm × 15-cm column that contains 4-μm packing L1 may be used. ] Flow rate: 1 mL/min Injection size: 20 μL System suitability Sample: Standard solution Suitability requirements Column efficiency: NLT 2000 theoretical plates Relative standard deviation: NMT 2.0% Analysis Samples: Standard solution and Sample solution Calculate the percentage of C34H36MgN6O6S2 in the portion of Esomeprazole Magnesium taken: Result = (rU/rS) × (CS/CU) × [Mr1/(2 × Mr2)] × 100 Acceptance criteria: 98.0%–102.0% on the anhydrous basis OTHER COMPONENTS • CONTENT OF MAGNESIUM Lanthanum solution: Transfer 58.7 g of lanthanum oxide into a 1000-mL volumetric flask, wet the substance with some water, and dissolve by cautious addition of 250 mL of hydrochloric acid in 20- to 30-mL portions, cooling between the additions. Add water while stirring, cool to room temperature, and dilute with water to volume. [NOTE—Store the solution in a plastic bottle. ] Standard stock solution: 1000 μg/mL of magnesium in water, from a commercially prepared atomic absorption standard solution. [NOTE—Store the solution in a plastic bottle. ] Standard solution A: Transfer 10.0 mL of Standard stock solution to a 500-mL volumetric flask, add 50 mL of 1 N hydrochloric acid, and dilute with water to volume. Transfer 20.0 rU = = peak response from the Sample solution rS = = peak response from the Standard solution CS = = concentration of omeprazole in the Standard solution (mg/mL) CU = = concentration of Esomeprazole Magnesium in the Sample solution (mg/mL) Mr1 = = molecular weight of esomeprazole magnesium, 713.12 Mr2 = = molecular weight of omeprazole, 345.42 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. [NOTE— This solution contains 2 μg/mL of magnesium. ] Standard solution B: Combine 5.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.1 μg/mL). Standard solution C: Combine 10.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.2 μg/mL). Standard solution D: Combine 15.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.3 μg/mL). Standard solution E: Combine 20.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.4 μg/mL). Standard solution F: Combine 25.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.5 μg/mL). [NOTE—Concentrations of the Standard solutions and the Sample solution may be modified to fit the linear or working range of the instrument. When using instruments with a linear calibration graph, the number of Standard solutions can be reduced. ] Blank solution: Transfer 4.0 mL of Lanthanum solution to a 100-mL volumetric flask, and dilute with water to volume. Sample solution: Transfer 250 mg of Esomeprazole Magnesium to a 100-mL volumetric flask, add 20 mL of 1 N hydrochloric acid, swirl until dissolved, and dilute with water to volume. Allow to stand for 30 min. Transfer 10.0 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. Transfer 10.0 mL of the solution to another 100-mL volumetric flask, add 4.0 mL of Lanthanum solution, and dilute with water to volume. Spectrometric conditions (See Spectrophotometry and Light-Scattering 851 .) Mode: Atomic absorption spectrophotometer Flame: Air–acetylene Analytical wavelength: 285.2 nm Analysis Samples: Standard solution B, Standard solution C, Standard solution D, Standard solution E, Standard solution F, Blank solution, and Sample solution Determine the concentration, Cs, in μg/mL, of magnesium in the Sample solution using the calibration graph. Calculate the percentage of magnesium in the portion of Esomeprazole Magnesium taken: Result = (CS/CU) × (100/(100 F)) × 100 CS = = content of magnesium in the Sample solution as calculated above (μg/mL) CU = = concentration of Esomeprazole Magnesium in the Sample solution (μg/mL) F = = content of water in Esomeprazole Acceptance criteria: 3.30%–3.55%, on anhydrous basis IMPURITIES Organic Impurities • PROCEDURE 1 Solution A: 0.725 g of monobasic sodium phosphate and 4.472 g of anhydrous dibasic sodium phosphate in 300 mL of water, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. If necessary, adjust with phosphoric acid to a pH of 7.6. Mobile phase: Acetonitrile and Solution A (11:29). [NOTE—To improve the resolution, the composition may be changed to 1:3, if necessary. ] System suitability solution: 1 mg of USP Omeprazole RS and 1 mg of USP Omeprazole Related Compound A RS in 25 mL of Mobile phase. [NOTE—Omeprazole Related Compound A is omeprazole sulfone. ] Sample solution: 4 mg of Esomeprazole Magnesium in 25 mL of Mobile phase. [NOTE— Prepare this solution fresh. ] Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 280 nm Column: 4.0-mm × 12.5-cm or a 4.6-mm × 15-cm; 5-μm packing L7. [NOTE— Alternatively, a 3.9-mm × 15-cm column that contains 4-μm packing L1 may be used. ] Flow rate: 0.8–1 mL/min Injection size: 50 μL System suitability Sample: System suitability solution [NOTE—For relative retention times, see Impurity Table 1. ] Suitability requirements Resolution: NLT 3 between omeprazole related compound A and omeprazole Analysis Sample: Sample solution Record the chromatogram for at least 4.5 times the retention time of the omeprazole peak, and measure the peak responses. Identify the impurities based on the retention times shown in Impurity Table 1. Calculate the percentage of any individual impurity in the portion of Esomeprazole Magnesium taken: Result = (rU/rT) × 100 Magnesium, as determined in Specific Tests, Water Determination (%) rU = = peak response for each impurity = = sum of all peak responses Acceptance criteria Individual impurities: See Impurity Table 1. Total impurities: NMT 0.5% Impurity Table 1 • PROCEDURE 2: ENANTIOMERIC PURITY Solution A: Mix 70 mL of 1 M monobasic sodium phosphate with 20 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. Diluent: Mix 11 mL of 0.25 M tribasic sodium phosphate with 22 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 1000 mL. Mobile phase: Acetonitrile and Solution A (3:17) System suitability solution: 2 mg of USP Omeprazole RS in 10 mL of Diluent. Dilute 1.0 mL of this solution with Diluent to 50 mL. Sample solution: 40 mg of Esomeprazole Magnesium in 5 mL of methanol, and dilute with Diluent to 25 mL. Dilute 1 mL of this solution with Diluent to 50 mL. Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 302 nm Column: 4.0-mm × 10-cm; packing L41 Flow rate: 0.6 mL/min Injection size: 20 μL System suitability Sample: System suitability solution Suitability requirements Resolution: NLT 3 between the enantiomer peaks. [NOTE—The elution order is the Renantiomer, followed by the esomeprazole peak, which is the S-enantiomer. ] Analysis rT Name Relative Retention Time Acceptance Criteria, NMT (%) Omeprazole N-oxide a 0.45 0.1 Omeprazole sulfoneb (related compound A) 0.8 0.2 Any other individual impurities — 0.1 Omeprazole 1.0 — a 4-Methoxy-2-[[(RS)-(5-methoxy-1H-benzimidazol-2-yl)sulfinyl]methyl]-3,5- dimethylpyridine 1-oxide. b 5-Methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]-1Hbenzimidazole. Sample: Sample solution Calculate the percentage of the R-enantiomer in the portion of Esomeprazole Magnesium taken: Result = (rU/rS) × 100 Acceptance criteria: NMT 0.2% of the R-enantiomer SPECIFIC TESTS • WATER DETERMINATION, Method I 921 : 6.0%–8.0% • COLOR OF SOLUTION Sample solution: 20 mg/mL of Esomeprazole Magnesium in methanol Analysis: Determine the absorbance of this solution at 440 nm, in 1-cm cells, using methanol as the blank. Acceptance criteria: NMT 0.2 ADDITIONAL REQUIREMENTS • PACKAGING AND STORAGE: Preserve in tight containers, protected from light. Store at room temperature. • USP REFERENCE STANDARDS 11 USP Esomeprazole Magnesium RS USP OMEPRAZOLE RS USP OMEPRAZOLE RELATED COMPOUND A RS Omeprazole sulfone, 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]- 1H-benzimidazole. C17H19N3O4S 361.42 [CAS-88546-55-8]. Auxiliary Information— Please check for your question in the FAQs before contacting USP. USP34–NF29 Page 2741 Pharmacopeial Forum: Volume No. 35(3) Page 550 Chromatographic Column— ESOMEPRAZOLE MAGNESIUM rU = = peak response for the R-enantiomer rS = = sum of the peak responses for esomeprazole and R-enantiomer Topic/Question Contact Expert Committee Monograph Elena Gonikberg, Ph.D. Principal Scientific Liaison 1-301-816-8251 (SM32010) Monographs - Small Molecules 3 Reference Standards RS Technical Services 1-301-816-8129 rstech@usp.org Chromatographic columns text is not derived from, and not part of, USP 34 or NF 29 还有EP7.0里面是三水合物的标准，如果需要可以联系我，或留下邮箱我把标准发给你！ |
3楼2011-08-30 14:44:06
4楼2011-08-30 14:50:28